

Brand Name: Andexxa/Ondexxya

Generic: andexanet α

Type: small molecule

Year Accepted/Phase: 2018

Mechanism:

Andexxa works by acting as a decoy molecule that binds to factor Xa inhibitors, sequestering them and restoring the activity of endogenous factor Xa, which can help in the formation of blood clots and control bleeding.

Chemical Structure: N/A

Indication:

Andexxa/Ondexxya is indicated for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

Clinical trials:

ANNEXA-A and ANNEXA-R Trials

Pubmed: <https://pubmed.ncbi.nlm.nih.gov/26559317/>

Purpose: Evaluate the efficacy and safety of andexanet alfa in reversing the anticoagulation effects of factor Xa inhibitors.

Dates: Conducted from 2015 to 2016.

Results: The ANNEXA-A and ANNEXA-R trials demonstrated that andexanet alfa rapidly and significantly reversed the anticoagulation effects of apixaban and rivaroxaban, respectively, as measured by anti-factor Xa activity. The reversal was also associated with a reduction in bleeding.

Impact: These results supported the approval of Andexxa/Ondexxya for the reversal of factor Xa inhibitor anticoagulation.